source
- Lilly, Ascidian link up in RNA exon editing pactWorth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.BioPharma Dive · 2mo ago↗ source
- Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trialGedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.BioPharma Dive · 2mo ago↗ source
- Lilly gives hospitals deadline to comply with 340B claims data policyEli Lilly is giving a group of hospitals five days to comply with its new claims data policy or risk losing their 340B discounts. Some health centers aren’t cooperating with Lilly's recent push to…